Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q969M7
UPID:
UBE2F_HUMAN
Alternative names:
NEDD8 carrier protein UBE2F; NEDD8 protein ligase UBE2F; NEDD8-conjugating enzyme 2; RING-type E3 NEDD8 transferase UBE2F; Ubiquitin-conjugating enzyme E2 F
Alternative UPACC:
Q969M7; A8K1Z8; B4DDT9; B4DFI1; B4DMK3; B4DZU2; B8ZZG2; C9J212; H9KVB9
Background:
NEDD8-conjugating enzyme UBE2F plays a pivotal role in protein modification, specifically in the process of neddylation. It accepts the ubiquitin-like protein NEDD8 from the UBA3-NAE1 E1 complex and catalyzes its attachment to target proteins. This enzyme's interaction with E3 ubiquitin ligase RBX2, as opposed to RBX1, indicates a selective mechanism for neddylating specific proteins such as CUL5.
Therapeutic significance:
Understanding the role of NEDD8-conjugating enzyme UBE2F could open doors to potential therapeutic strategies.